Vogenx begins Phase 2b EMERGE study for post-bariatric hypoglycemia
+1 new source since this summary was written
On October 15, 2026, Vogenx said it had started the EMERGE Phase 2b study of mizagliflozin in adults with post-bariatric hypoglycemia. The trial is planned to include approximately 36 adults and compares 5 mg, 10 mg and placebo, administered three times daily for 28 days. The company said no U.S. FDA-approved therapy currently exists for the condition.
Why it matters
The trial advances mizagliflozin into a controlled mid-stage study for a condition without an FDA-approved treatment. Its design is intended to measure whether the drug reduces combined Level 2 and Level 3 hypoglycemic events, but the materials provide no clinical results from this study.
Key facts
- 1The EMERGE study uses a three-week run-in period before treatment assignment. stocktitan.net
- 2The study's main efficacy measure is the combined count of Level 2 and Level 3 hypoglycemic events. stocktitan.net
- 3Vogenx expects the trial to operate at approximately 10 U.S. sites. stocktitan.net
- 4The study is registered as NCT07760961. stocktitan.net
- 5Mizagliflozin has been given to more than 500 subjects across 10 clinical studies, according to Vogenx. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.